Bicara Therapeutics Inc (BCAX) saw an uptrend of 4.25% in the recent trading with $18.15 being its most recent. The current price level -35.39% lower than the highest price of $28.09 marked by the stock while trading over the past 52-weeks, whereas it is 5.65% higher than the lowest price of $17.18 the company dropped to over past 52-weeks. The latest news story on BCAX appeared in (GlobeNewswire) under the title “Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update”.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Sponsored
Squeezing the time span to 30 day period shows us the stock is currently trading -19.96% below one month high and is +6.76% above of the lowest during that time. Looking into the simple moving average, Bicara Therapeutics Inc (BCAX)’s stock stands at a SMA-50 of $21.01 while that of 5-day is reading $18.20.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Bicara Therapeutics Inc Earnings – What Happened With BCAX
Coming around sales and income figures on BCAX Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
BCAX – Bicara Therapeutics Inc Stock Earnings Estimates
3 analysts covering the stock at Wall Street were agreed upon that EPS consensus.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 54.41 million. BCAX does have institutional investors; and they hold 45.40% of the stock.
Bicara Therapeutics Inc – Insider Activity and Holdings
Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Bicara Therapeutics Inc has a debt to equity ratio of 0.00.
